Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13858427 | 0.98 | ALDH1A1 (0.45) | ALDH1A1HSD17B10HPGDCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL30584731 | 0.98 | ALDH1A1 (0.45) | ALDH1A1HSD17B10HPGDCYP1A2CYP2D6 | |
| SCHEMBL29791494 | 0.86 | GRIN1 (0.46) | CYP1A2MEN1KMT2AGRIN1GRIN2A | |
| SCHEMBL29730766 | 0.82 | GRIN1 (0.51) | ALDH1A1CYP1A2MEN1KMT2AGRIN1 | |
| SCHEMBL29730787 | 0.81 | GRIN1 (0.54) | ALDH1A1CYP1A2GRIN1GRIN2AGRIN2B | |
| SCHEMBL13447345 | 0.81 | GRIN1 (0.54) | ALDH1A1CYP1A2GRIN1GRIN2AGRIN2B | |
| SCHEMBL6887227 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDCYP1A2CYP2D6 | |
| SCHEMBL29602661 | 0.78 | OPRM1 (0.53) | ALDH1A1HSD17B10HPGDCYP1A2CYP2D6 | |
| SCHEMBL171507 | 0.78 | OPRM1 (0.53) | ALDH1A1HSD17B10HPGDCYP1A2CYP2D6 | |
| SCHEMBL746867 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804791-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049880-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | claimed |
| US-20220081441-A1 | CYCLOALKYLUREA DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-03-17 | — | — | US | disclosed |
| EP-3883928-A1 | GLP-1R AGONISTS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2021-09-29 | — | — | EP | disclosed |
| EP-2709451-B1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2709451-B1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| WO-2012158475-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2515656-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| WO-2011084371-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1682141-A1 | 4-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | ALDH1A1 2997/4885HSD17B10 3648/4885HPGD 2412/4885 |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, MTNR1B | ALDH1A1 2379/4885HSD17B10 3692/4885HPGD 3012/4885 |
| US-20220081441-A1 | CYCLOALKYLUREA DERIVATIVE | HCRTR2, HCRTR1, CRHR2 | ALDH1A1 2531/4885HSD17B10 2701/4885HPGD 2437/4885 |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | OPRL1, HVCN1, TRPV1 | ALDH1A1 1112/4885HSD17B10 3260/4885HPGD 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.